SOUTH SAN FRANCISCO, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced the virtual unveiling of its manufacturing facility, Cell Forge 1 (“CF1”), located in Newark, California. The 136,000-square-foot facility is designed to support clinical trial and potential commercial production and worldwide distribution of allogeneic CAR T cell products for blood cancers and solid tumors. The virtual platform, designed to create an interactive and engaging CF1 virtual experience, includes welcome remarks from Allogene’s President, Chief Executive Officer and Co-Founder, David Chang, M.D., Ph.D., corporate and scientific videos, a 360° virtual tour of the facility, and a patient gallery.
Read more at globenewswire.comhello world
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
